Neurosense Therapeutics Ltd. (NRSN)
US Market

Neurosense Therapeutics Ltd. (NRSN) Stock Price & Analysis


NRSN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.08 - $4.47
Previous Close$1.6
Average Volume (3M)52.86K
Market Cap
Enterprise Value$15.43M
Total Cash (Recent Filing)$3.58M
Total Debt (Recent Filing)$147.00K
Price to Earnings (P/E)-1.5
May 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding11,781,963
10 Day Avg. Volume50,473
30 Day Avg. Volume52,864
Standard Deviation0.46
Financial Highlights & Ratios
Price to Book (P/B)3.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit200.38
Enterprise Value/Ebitda-1.69
Price Target Upside357.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $1.07 and its highest was $4.47 in the past 12 months.
    What is Neurosense Therapeutics Ltd.’s market cap?
    Currently, no data Available
    When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
    Neurosense Therapeutics Ltd.’s upcoming earnings report date is May 30, 2023 which is yesterday.
      How were Neurosense Therapeutics Ltd.’s earnings last quarter?
      Neurosense Therapeutics Ltd. released its earnings results on Mar 22, 2023. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.01.
        Is Neurosense Therapeutics Ltd. overvalued?
        According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Neurosense Therapeutics Ltd. pay dividends?
          Neurosense Therapeutics Ltd. does not currently pay dividends.
          What is Neurosense Therapeutics Ltd.’s EPS estimate?
          Neurosense Therapeutics Ltd.’s EPS estimate is -$0.29.
            How many shares outstanding does Neurosense Therapeutics Ltd. have?
            Neurosense Therapeutics Ltd. has 11,790,963 shares outstanding.
              What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
              Neurosense Therapeutics Ltd. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -4.624%.
                Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
                Currently, no hedge funds are holding shares in NRSN


                Neurosense Therapeutics Ltd. Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Neurosense Therapeutics Ltd.

                NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Chemomab Therapeutics
                Entera Bio

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis